Heparin Management During Cardiopulmonary Bypass in Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nina Guzzetta, M.D., Emory University
ClinicalTrials.gov Identifier:
NCT00146653
First received: September 2, 2005
Last updated: November 19, 2013
Last verified: November 2013
  Purpose

We propose a comparison between between our standard ACT based heparin management protocol for children undergoing CPB and a patient-specific heparin concentration-based heparin management protocol. We hypothesize that a heparin concentration-based anticoagulation management protocol during CPB in children will result in more effective attenuation of hemostatic activation as reflected by decreased levels of thrombin formation and, ultimately, better preservation of hemostasis postoperatively.

An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention.


Condition
Primary Condition: Heart Defects Requiring Surgery With CPB

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Comparison of Heparin Management Strategies in Children Undergoing Cardiopulmonary Bypass.

Resource links provided by NLM:


Further study details as provided by Emory University:

Primary Outcome Measures:
  • Xa sample is being collected to validate the results from the Hepcon Assay. The Hepcon results are being compared to the Hemochron and iStat ACT results. [ Time Frame: The Xa sample is being collected before the initiation of cardiopulmonary bypass and immediately prior to the discontinuation of cardiopulmonary bypass. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Transfusion requirements and patient bleeding postoperatively. [ Time Frame: Postoperatively ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Blood is being collected to obtain Xa results.


Enrollment: 20
Study Start Date: December 2005
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Xa
An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .

Detailed Description:

40 patients will be randomly assigned to either the traditional heparin management group or the intervention group. The traditional group will be treated with an initial heparin dose of 400 units/kg and the standard amount of heparin, as dictated by the circuit size, will be added to the CPB circuit prime. An ACT target value of 480 seconds will be maintained throughout the bypass period. Should the ACT fall below 480 seconds,additional boluses of 100 units/kg of heparin will be given until the ACT returns to the target value. At the end of CPB, heparin will be neutralized by the standard reversal of 4 mg/kg of protamine.

An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention.

For the intervention group, a heparin dose (HDR) response assay will be performed prior to surgical incision by the Hepcon instrument. The hepcon machine performs a patient-specific HDR assay based on body surface area, and determines a projected heparin concentration required by that patient to achieve an ACT of 480 seconds. The HDR assay provides the initial dose of heparin to give the patient as well as the amount of heparin to be added to the CPB circuit. Additional heparin doses as determined by the hepcon instrument will be administered as needed if the patient's heparin concentration falls below the projected reference concentration. The hepcon instrument will also calculate the protamine dose needed to reverse heparin at the end of CPB.

For comparison between groups, an assay using the hepcon machine to measure whole blood heparin concentration and an ACT will be obtained for each patient at the following intervals: after the initial heparin dose, 30 minutes after the initiation of CPB, the start of rewarming and immediately prior to the discontinuation of CPB. A sample for anti-factor Xa activity will also be obtained at each of the above time intervals to validate the heparin concentration determined by the hepcon machine to a laboratory measured value. Blood samples for biochemical markers of hemostatic activation will be collected from all patients before the initiation of CPB after the administration of the initial heparin dose and after the conclusion of CPB before protamine infusion. The following biochemical markers of hemostatic activation will be measured: prothrombin fragment 1.2, fibrinopeptide A, free tissue factor pathway inhibitor, factor V, factor VIII, and beta-thromboglobulin. The following measures of clinical outcome will also be recorded: amount of blood products transfused after protamine administration, time between the administration of protamine to leaving the operating room, 24-hour chest tube drainage, first post-operative weight, time to extubation and duration of ICU stay.

Additional 20 patients: These additional 20 patients will be enrolled to provide further validation of the Hepcon-measured heparin concentrations with the laboratory-measured heparin concentrations (anti-factor Xa activity). A blood sample will be obtained for a heparin dose response (HDR) assay prior to surgical incision Samples will also be obtained to measure a heparin concentration by the Hepcon machine and by anti-factor Xa activity at two time periods: after the initial heparin dose and immediately prior to discontinuation of CPB. In addition, these 20 patients will also have an ACT test analyzed by the Hepcon machine after protamine is given.

  Eligibility

Ages Eligible for Study:   up to 6 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients will be obtained from the patient's of Children's Healthcare of Atlanta at Egleston. These patients will be obtained from the pre-operative clinc, the Cardiac Intensive Care Unit or the Cardiac Stepdown unit.

Criteria

Inclusion Criteria:

  1. Patients undergoing elective cardiac surgical procedures requiring CPB at Children's Healthcare of Atlanta at Egleston.
  2. Patients less than 6 months old.
  3. Parent/legal guardian willing to sign consent. -

Exclusion Criteria:

  1. Patients presenting for emergency surgery.
  2. Patients treated preoperatively with anticoagulant therapy.
  3. Patients treated with antifibrinolytics during their cardiac surgery.
  4. Parent/legal guardian unwilling or unable to sign consent. -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00146653

Locations
United States, Georgia
Children's Healthcare of Atlanta at Egleston
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Nina A Guzzetta, MD Emory University
  More Information

Publications:
Responsible Party: Nina Guzzetta, M.D., Assistant Professor of Anesthesiology, Emory University
ClinicalTrials.gov Identifier: NCT00146653     History of Changes
Other Study ID Numbers: 286-2005
Study First Received: September 2, 2005
Last Updated: November 19, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Emory University:
pediatrics
cardiopulmonary bypass
surgery

Additional relevant MeSH terms:
Heparin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on October 01, 2014